What about Beijing Kane Technology Co., Ltd.?

Beijing Kane Technology Co., Ltd. (hereinafter referred to as Kane Technology) was established in 2008 with a registered capital of 75.3 million yuan. Based on biotechnology, the company focuses on the field of liver diseases and is committed to becoming a professional listed company providing health solutions. 20 10 shareholding system reform, Lenovo Investment (Junlian Capital) was introduced in June, and Haitong Kaiyuan and other strategic partners were introduced in May. 20 1 1, selected as the top leading enterprise in Zhongguancun and one of the top 100 cutting-edge enterprises in Zhongguancun.

The company's R&D team consists of nearly 30 overseas experts, doctors and masters, and is guided by the famous molecular virologist Academician Hou Yunde. The vice president of R&D is Dr. Pan Hai, a senior scientist who once worked for Amgen, the world's largest biopharmaceutical company. In an integrated and innovative way, on the basis of major national science and technology projects such as the Eleventh Five-Year Plan and the Twelfth Five-Year Plan, we will develop a series of innovative drugs with independent intellectual property rights, and establish a series of product patterns such as anti-virus, immunity enhancement, liver protection, anti-hepatic fibrosis and anti-liver cancer. R&D Center is "Beijing Recombinant Protein Pharmaceutical Engineering Technology Research Center". At present, the company is carrying out 19 R&D projects, including 6 biological products R&D projects; 7. Chemical R&D projects; 6 technical platform projects.

Kane Technology has 7 GMP workshops for biological products and chemicals, with 5 varieties listed/kloc-0. Its leading product, recombinant human interferon α2b, ranked first in the market for four consecutive years, followed by compound glycyrrhizin for two consecutive years and naloxone hydrochloride for four consecutive years. Products have been exported or registered in 13 countries.

Development goals:

Through concentration and specialization, Kane Technology has become a leading brand enterprise in the field of liver disease.

The company plans to be listed on the domestic growth enterprise market on 20 14, with a market value of over 2 billion yuan.

Cain culture

Excellence: Excellence, Excellence first.

Innovation: embrace change and be passionate about innovation.

Cooperation: delivery of results and win-win cooperation.

Execution: perfect action, winning lies in execution.

corporate vision

Professional quality and healthy life

Based on biotechnology, focusing on the field of liver diseases, we are committed to becoming a professional public company providing health solutions.

Salary and benefits

The company provides competitive salary and benefits: good working environment, perfect training mechanism, broad development platform and clear career development direction.

Existing advantages:

Five insurances and one gold;

Commercial medical insurance;

Paid annual leave;

Annual free medical examination;

Meal supplement;

Shuttle bus;

Staff quarters;

Festival fee and high temperature heatstroke prevention and cooling fee;

Beijing Kane sincerely looks forward to your arrival. Join Kane, and you will truly win the win-win and honor of employees and enterprises.

Recruitment mailbox :zhaopin@kawin.com.cn

Legal Representative: Zhou Desheng.

Date of establishment: August 20, 2008

Registered capital: 65,438+0,265,438+0,000 yuan.

Area: Beijing.

Unified social credit code: 91110302678753566.

Business status: Opening.

Industry: scientific research and technical services

Company type: joint-stock company (Taiwan, Hong Kong, Macao and China joint venture, unlisted)

English name: Beijing kaiwei technology co., ltd.

Number of employees: 100-499.

Address: Building 3, No.6 Rong JD.COM Street, Beijing Economic and Technological Development Zone.

Business scope: production of therapeutic biological products (recombinant human interferon a2b injection, recombinant human interferon a2b for injection, recombinant human interferon a2b vaginal effervescent tablets, cultured interferon a-2 injection and recombinant human interferon a2a injection), small-volume injections, freeze-dried powder injections, tablets, hard capsules and granules; Import and export of goods, technologies and agents; Technology development, technology consultation, technology transfer and technical services; Equipment leasing; Property management. (This enterprise was changed from a domestic-funded enterprise to a foreign-invested enterprise on July 28th, 20 15 (date of approval)). Projects that must be approved according to law shall, after being approved by the relevant departments, carry out business activities in accordance with the approved contents. )